The Market for Non-Small-Cell Lung Cancer (NSCLC) Will Grow to $7 Billion in 2022, Fuelled by the Entry of Twelve Novel Agents
NSCLC Treatment Will Become Increasingly Personalized Due to Emergence of Novel Targeted Therapies with Companion Diagnostic Tests, According to Findings from Decision Resources
BURLINGTON, Mass., Dec. 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry of twelve new therapies into the non-small-cell lung cancer (NSCLC) drug market will drive the market's growth from $4.9 billion in 2012 to over $7 billion in 2022. The approval of three immunotherapies, the entry of second generation ALK and EGFR inhibitors, as well as continued uptake of Pfizer's Xalkori and EGFR inhibitors particularly in the advanced/metastatic first-line treatment setting will drive the growth of the NSCLC drug market. This market growth will occur despite the generic erosion of key branded current therapies including Eli Lilly's Alimta and Genentech/Roche/Chugai/Astellas's Tarceva.
(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )
The Pharmacor Non-Small-Cell Lung Cancer advisory service also finds that treatment of NSCLC is becoming increasingly personalized, driven by the accumulation of positive data of current and novel therapies in molecularly defined populations. The expected approvals of Novartis's ceritinib (LDK-378) and Chugai/Roche's alectinib for Xalkori-treated patients further advances the personalized treatment approach in NSCLC, offering a targeted second-line standard-of-care therapy for ALK-translocation positive patients.
"The majority of the agents in the NSCLC pipeline are being developed to target specific molecular targets," said Decision Resources Business Insights Analyst Orestis Mavroudis-Chocholis, Ph.D. "In the next ten years, we expect the launch of seven agents positioned to treat specific molecularly defined patient subpopulations—Pfizer's dacomitinib, Genentech/Roche/Chugai's onartuzumab, ceritinib, alectinib, Bristol-Myers Squibb/Ono Pharmaceutical's nivolumab, Merck's MK-3475 (formerly known as lambrolizumab) and AstraZeneca's selumetinib."
The report also finds that the unmet needs for more efficacious therapies for squamous-cell NSCLC patients and those harboring KRAS mutations will be addressed to some extent by the approval of novel therapies, Eli Lilly's necitumumab and selumetinib, respectively. However, significant unmet need remains particularly for these underserved patient populations.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article